Peer Review reports
From: Neo-adjuvant chemotherapy plus immunotherapy in resectable N1/N2 NSCLC
| Original Submission | ||
|---|---|---|
| 22 Aug 2023 | Submitted | Original manuscript |
| 24 Sep 2023 | Reviewed | Reviewer Report |
| 18 Oct 2023 | Reviewed | Reviewer Report |
| 8 Nov 2023 | Author responded | Author comments - Zhengliang Tu |
| Resubmission - Version 2 | ||
| 8 Nov 2023 | Submitted | Manuscript version 2 |
| 10 Nov 2023 | Author responded | Author comments - Zhengliang Tu |
| Resubmission - Version 3 | ||
| 10 Nov 2023 | Submitted | Manuscript version 3 |
| 11 Nov 2023 | Author responded | Author comments - Zhengliang Tu |
| Resubmission - Version 4 | ||
| 11 Nov 2023 | Submitted | Manuscript version 4 |
| 23 Nov 2023 | Reviewed | Reviewer Report |
| 5 Dec 2023 | Reviewed | Reviewer Report |
| 7 Dec 2023 | Author responded | Author comments - Zhengliang Tu |
| Resubmission - Version 5 | ||
| 7 Dec 2023 | Submitted | Manuscript version 5 |
| Publishing | ||
| 12 Dec 2023 | Editorially accepted | |
| 21 Dec 2023 | Article published | 10.1186/s12885-023-11745-x |
You can find further information about peer review here.